$57.080
-2.089 (-3.66%)終値時点
BRKR のニュース
BRKR のイベント
Bruker Corporation Expands Strategic Collaboration with Atinary Technologies
Bruker Corporation announced an expanded strategic collaboration with Atinary Technologies. Financial details were not disclosed. Atinary intends to integrate Chemspeed configurable laboratory automation platforms, Bruker analytical instruments and SciY scientific software into its agentic AI workflows.
Bruker Shares Drop 18.2% to $52.61
Bruker is down -18.2%, or -$11.70 to $52.61.
Major Averages Surge Again, Tech Shares Lead Gains
The major averages were sharply higher once again, building on Monday's gains as technology shares continue to lead gains and oil prices continue to drop. Strong quarterly reports from big firms such as Palantir, Caterpillar, and McDonald's helped fuel broad increases, while optimism remains over a U.S.-Iran deal to reopen the Strait of Hormuz potentially on the horizon.Meanwhile, investors are also monitoring reports that the Trump administration is drafting restrictions on certain Chinese-made data center networking components over national security concerns, a move that could have implications for AI infrastructure and semiconductor supply chains.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Palantirprovided areport for Q2Caterpillarreportedand provided its outlook for Q3 and FY26 revenueMcDonald'sreported, while global comparable sales rose 1.3% year-over-yearPfizerreported better-than-expected Q3 earnings and revenue andMerckreportedbut lowered its FY26 earnings outlook2. WALL STREET CALLS:Deutsche BankPalantirto Buy after "exceptional" Q2JPMorganNiketo Underweight on below-consensus estimatesOppenheimerInspire Medicaldespite "noisy" fundamentalsWalmartto Perform at OppenheimerJPMorganPVHto Underweight on estimate risk3. AROUND THE WEB:A Senate report alleges Deutsche Bankand Bank of Americafailed to timely report hundreds of millions of dollars in suspicious transactions linked to Jeffrey Epstein-related accounts, calling for investigations and tougher penalties for compliance failures, Bloomberg reportsApplehas launched a legal complaint at the Investigatory Powers Tribunal over the UK's latest attempt to create a "backdoor" that would allow it to access encrypted customer data, FT saysAnthropic has secured a $10B computing capacity agreement with Nvidia-backed Volta Infra to expand data center access and meet rising demand for its Claude AI products, Bloomberg reportsThe Trump administration has invited staffers from OpenAI, Google, Anthropic, and others to the White House on Tuesday to review the AI oversight framework, The Information saysA review by the New York Times of a dozen lawsuits against Uberby riders that were sexually assaulted or harassed on their rides found the company will scour women's private communications, medical records, and past assaults, using this information to present the women as unreliable narrators of the incidents4. MOVERS:Backblazehigher after, providing guidance for Q3, raising its outlook for FY26, and registering to sell 4.19M shares of stockAmeresco (AMRC) increases after, providing guidance for FY26, and after BNP Paribas upgraded the stock to OutperformPaymentusand Wayfairgain afterClearPoint Neurofalls afterand cutting its guidance for FY26AdaptHealthand Brukerlower after5. EARNINGS/GUIDANCE:Syscoand provided guidance for FY27Shoals Technologies, with EPS and revenue beating consensusBellRing Brandsand raised its outlook for FY26Centurithat CEO Christian Brown said "reflect tremendous year-over-year growth"Graingerand raised its guidance for FY26INDEXES:Near midday, the Dow was up 922.33, or 1.73%, to 54,100.74, the Nasdaq was up 529.64, or 2.04%, to 26,443.54, and the S&P 500 was up 111.50, or 1.47%, to 7,712.00.
Bruker Shares Down 18.4% to $52.47
Bruker is down -18.4%, or -$11.85 to $52.47.
Bruker Reports Q2 Revenue of $838.5M
Reports Q2 revenue $838.5M, consensus $853.57M. Frank Laukien, Bruker's President and CEO, commented: "We returned to organic revenue growth in the second quarter and our Scientific Instruments segment achieved 10% organic bookings growth year-over-year. Our focus on cost and profitability resulted in solid margin expansion and non-GAAP EPS growth in the quarter. In particular, we achieved strong order bookings growth for our differentiated products and solutions in the semiconductor tools, energy research and biopharma markets. In our academic and medical research business, US academic demand remained soft in Q2, while aca/gov bookings in Europe and China were up strongly. We are gaining confidence in a gradual market recovery, and we anticipate significant organic margin expansion and non-GAAP EPS growth not only this year, but in 2027 as well."
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。






